140 related articles for article (PubMed ID: 33813119)
1. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis.
Onorato L; Gentile V; Russo A; Di Caprio G; Alessio L; Chiodini P; Coppola N
Clin Microbiol Infect; 2021 Jun; 27(6):830-837. PubMed ID: 33813119
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: Systematic review and meta-analysis.
Charlie L; Abay SM; Tesfaye A; Mlera RN; Mwango S; Goretti M
Int J Mycobacteriol; 2021; 10(3):312-319. PubMed ID: 34494572
[TBL] [Abstract][Full Text] [Related]
3. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
Trials; 2020 May; 21(1):383. PubMed ID: 32370774
[TBL] [Abstract][Full Text] [Related]
4. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
5. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
7. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
8. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Heinrich N; Dawson R; du Bois J; Narunsky K; Horwith G; Phipps AJ; Nacy CA; Aarnoutse RE; Boeree MJ; Gillespie SH; Venter A; Henne S; Rachow A; Phillips PP; Hoelscher M; Diacon AH; ;
J Antimicrob Chemother; 2015 May; 70(5):1558-66. PubMed ID: 25630641
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis.
Schwander S; Rüsch-Gerdes S; Mateega A; Lutalo T; Tugume S; Kityo C; Rubaramira R; Mugyenyi P; Okwera A; Mugerwa R
Tuber Lung Dis; 1995 Jun; 76(3):210-8. PubMed ID: 7548903
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
Milstein M; Lecca L; Peloquin C; Mitchison D; Seung K; Pagano M; Coleman D; Osso E; Coit J; Vargas Vasquez DE; Sanchez Garavito E; Calderon R; Contreras C; Davies G; Mitnick CD
BMC Infect Dis; 2016 Aug; 16(1):453. PubMed ID: 27567500
[TBL] [Abstract][Full Text] [Related]
11. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
[TBL] [Abstract][Full Text] [Related]
12. Fully intermittent dosing with drugs for treating tuberculosis in adults.
Mwandumba HC; Squire SB
Cochrane Database Syst Rev; 2001; (4):CD000970. PubMed ID: 11687088
[TBL] [Abstract][Full Text] [Related]
13. Fully intermittent dosing with drugs for tuberculosis.
Mwandumba HC; Squire SB
Cochrane Database Syst Rev; 2000; (4):CD000970. PubMed ID: 11034692
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
17. Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis.
Li D; Wang T; Shen S; Cheng S; Yu J; Zhang Y; Zhang C; Tang H
PLoS One; 2015; 10(12):e0145066. PubMed ID: 26669635
[TBL] [Abstract][Full Text] [Related]
18. Fully intermittent dosing with drugs for tuberculosis.
Mwandumba HC; Squire SB
Cochrane Database Syst Rev; 2000; 2001(2):CD000970. PubMed ID: 10796561
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin-induced disseminated intravascular coagulation in pulmonary tuberculosis treatment: A case report and literature review.
Chen G; He JQ
Medicine (Baltimore); 2017 Feb; 96(7):e6135. PubMed ID: 28207542
[TBL] [Abstract][Full Text] [Related]
20. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
